SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.…
Scynexis: Q3 Earnings Snapshot
SCYNEXIS (NASDAQ: SCYX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 18 employees.
The shares were at 2.380 USD on 20 November 2026, down 50.1% over 52 weeks. Its 52-week range is 2.300 USD to 9.120 USD: the price is 73.9% below the high and 3.5% above the low.
Its market capitalisation is 23.69M USD.
SCYNEXIS reports return on equity of -17.4% and an operating margin of -126.9%.
It holds more cash than debt, a net cash position of 45.34M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. The next earnings report is expected on 3 March 2027.